Nova Leah provides cybersecurity risk assessment solutions tailored for connected medical devices through its platforms, SelectEvidence® and SelectEvaluate®. These tools enable medical device manufacturers and healthcare providers to efficiently manage third-party risk and comply with FDA cybersecurity requirements, significantly reducing risk management cycles from 12 weeks to under one hour.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVFounders
Product
Problem
Medical device manufacturers and healthcare providers face increasing challenges in managing cybersecurity risks associated with connected medical devices, particularly with evolving FDA cybersecurity requirements. Traditional third-party risk management processes are often lengthy and inefficient, creating delays and potential vulnerabilities.
Solution
Nova Leah offers cybersecurity risk management solutions designed specifically for connected medical devices, enabling both manufacturers and healthcare providers to streamline their risk management processes and meet FDA cybersecurity requirements. The SelectEvidence® platform helps manufacturers manage cyber risks and automate responses to security questionnaires, while SelectEvaluate® allows healthcare providers to streamline third-party risk management from pre-procurement to device decommissioning. These platforms significantly reduce risk management cycles, improve cybersecurity posture, and facilitate compliance with evolving regulatory standards.
Target Audience
The primary customers are medical device manufacturers seeking to comply with FDA cybersecurity requirements and healthcare providers aiming to streamline third-party risk management for connected medical devices.
Features
- SelectEvidence™ for medical device manufacturers: Manages cyber risk and automates security questionnaire responses.
- SelectEvaluate® for healthcare providers: Streamlines third-party risk management from procurement to decommissioning.
- Reduces third-party risk management cycles from 12 weeks to under one hour.
- Facilitates compliance with FDA cybersecurity requirements.
- Provides a single location for manufacturers to connect with potential customers and monitor device cybersecurity.
- Supports pre- and post-market cybersecurity risk management, including threat modeling and vulnerability assessments.
- Enables creation, updating, and monitoring of Software Bill of Materials (SBOM).
- Supports coordinated vulnerability disclosure strategies.